Mixed Phenotype Acute Leukemia Clinical Trials

26 recruiting

Frequently Asked Questions

Common questions about Mixed Phenotype Acute Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Phase 1Phase 2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting
Phase 3

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Mixed Phenotype Acute LeukemiaLymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+3 more
Children's Oncology Group440 enrolled229 locationsNCT05602194
Recruiting
Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 1

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic Leukemia+6 more
Fred Hutchinson Cancer Center120 enrolled1 locationNCT04375631
Recruiting
Phase 4

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital850 enrolled3 locationsNCT06289673
Recruiting
Phase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06390319
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 1

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndromes+1 more
Orca Biosystems, Inc.300 enrolled9 locationsNCT03802695
Recruiting
Phase 2

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic SyndromesMixed Phenotype Acute LeukemiaLeukemia, Myeloid, Acute
Orca Biosystems, Inc.80 enrolled5 locationsNCT07216443
Recruiting
Phase 1

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06034470
Recruiting
Phase 1Phase 2

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+5 more
PedAL BCU, LLC960 enrolled182 locationsNCT04726241
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled8 locationsNCT06533579
Recruiting
Phase 1

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia+2 more
OHSU Knight Cancer Institute20 enrolled1 locationNCT04872790
Recruiting
Phase 1

Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

Acute Myeloid LeukemiaMyelodysplastic SyndromesMixed Phenotype Acute Leukemia+1 more
Stanford University24 enrolled1 locationNCT06551584
Recruiting
Phase 1Phase 2

A Study of Revumenib and Mezigdomide in People With Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Memorial Sloan Kettering Cancer Center52 enrolled10 locationsNCT07356154
Recruiting
Phase 2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more
Fred Hutchinson Cancer Center54 enrolled1 locationNCT06013423
Recruiting
Phase 2

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

CD19 PositiveMixed Phenotype Acute Leukemia (MPAL)
West Virginia University78 enrolled1 locationNCT07222579
Recruiting
Phase 3

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology160 enrolled112 locationsNCT05327894
Recruiting
Phase 1

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia
Meryx, Inc.50 enrolled3 locationsNCT04872478
Recruiting
Phase 1Phase 2

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center75 enrolled1 locationNCT03128034